58 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
GRFS Grifols, S.A. $20.42 $13.96B Downtrend
Article Searches
Is Grifols, S.A. (GRFS) a Great Stock for Value Investors? http://www.zacks.com/stock/news/323331/is-grifols-sa-grfs-a-great-stock-for-value-investors?cid=CS-ZC-FT-323331 Sep 17, 2018 - Is Grifols, S.A. (GRFS) a great pick from the value investor's perspective right now? Read on to know more.
36 'Safer' Dividend Healthcare WallStars For September https://seekingalpha.com/article/4205942-36-safer-dividend-healthcare-wallstars-september?source=feed_all_articles Sep 12, 2018 - Gilead took September's net gain safer Healthcare WallStar top spot. Its projected 21.82% net gain was 3% better than AbbVie's, and 29% more than Grifol's result, per analyst targets 9/10/18.WallStars
Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September https://seekingalpha.com/article/4205864-aceto-72-percent-target-net-gain-tops-wallstar-healthcare-equities-september?source=feed_all_articles Sep 12, 2018 - But for PMD, Big pharma drug makers and biotech continued to top the healthcare sector by yield and broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare s
GRFS: Barclays starts at Overweight http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180601083059 Jun 01, 2018 - Barclays issues rating change for GRFS
Grifols S.A. goes ex-dividend tomorrow https://seekingalpha.com/news/3360791-grifols-s-goes-ex-dividend-tomorrow?source=feed_news_all May 31, 2018 - Grifols S.A. (NASDAQ:GRFS) had declared $0.250975/share semi-annual dividend.Payable June 5; for shareholders of record May 31; ex-div June 1.
'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets https://seekingalpha.com/article/4177005-safer-dividend-healthcare-top-wallstar-gainers-gilead-sanofi-amerisource-anthem-johnson-per?source=feed_all_articles May 24, 2018 - Gilead took net gain safer May dividend Healthcare WallStar honors. Its 27.4% net gain was 23% better than Sanofi's, and 32% ahead of AmerisourceBergen's result per analyst targets of 5/22/18.22 of 31
3Pea Is A Payment Processor With >40% Organic Growth Selling For Half Of Peer Multiples https://seekingalpha.com/article/4176361-3pea-payment-processor-40-percent-organic-growth-selling-half-peer-multiples?source=feed_tag_editors_picks May 22, 2018 - Payments processor serving the niche plasma donation market. Share winner in a growing industry with revenue potentially 4-8x higher in four years.Strong financial profile with high margins, ROIC, and
Engadine Partners LLP Buys Grifols SA, Monster Beverage Corp, Sells GCP Applied Technologies ... http://www.gurufocus.com/news/679429/engadine-partners-llp-buys-grifols-sa-monster-beverage-corp-sells-gcp-applied-technologies-inc-cocacola-european-partners-plc May 09, 2018 - Engadine Partners LLP Buys Grifols SA, Monster Beverage Corp, Sells GCP Applied Technologies Inc, Coca-Cola European Partners PLC, Stocks: GRFS,MNST,GCP,CCE,, release date:May 09, 2018
Now Could Be The Right Time To Buy Grifols With Worries Over Trade With China https://seekingalpha.com/article/4162177-now-right-time-buy-grifols-worries-trade-china?source=feed_sector_healthcare Apr 10, 2018 - Sales and earnings growth have been tremendous.Profit margins were over 15% last year.The annual report was just released.The stock may be down on worries with China trade.
3 Things In Biotech, March 11: Aradigm Retries, Pfizer Glides, VBL Crashes https://seekingalpha.com/article/4155401-3-things-biotech-march-11-aradigm-retries-pfizer-glides-vbl-crashes?source=feed_sector_healthcare Mar 12, 2018 - Aradigm and Grifols try for European approval.Pfizer's GI advisory committee goes rather smoothly.VBL Therapeutics fails on glioblastoma treatment.

Pages: 123456

Page 1>

Related Companies

Name Exchange Price Mkt Cap
BMRN BioMarin Pharmaceutical Inc. NASDAQ $98.11 $17.42B
SRPT Sarepta Therapeutics, Inc. NASDAQ $152.52 $10.13B
NKTR Nektar Therapeutics NASDAQ $58.29 $10.05B
PRGO Perrigo Company NYSE $72.57 $9.93B
JAZZ Jazz Pharmaceuticals plc NASDAQ $161.01 $9.73B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Grifols, S.A.